Michael S. Gordon
YOU?
Author Swipe
View article: Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer
Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer Open
NCT03410030.
View article: 8P Botensilimab plus balstilimab in an expanded cohort of 123 patients with metastatic microsatellite-stable colorectal cancer and no active liver metastases
8P Botensilimab plus balstilimab in an expanded cohort of 123 patients with metastatic microsatellite-stable colorectal cancer and no active liver metastases Open
View article: A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer
A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer Open
Telaglenastat in combination with nivolumab was generally well tolerated. The combination did not show a pattern of efficacy across different study cohorts.
View article: Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer Open
Background Novel treatment options are required in patients with platinum-resistant ovarian cancer (PROC). Myeloid-derived suppressor cells promote a hostile tumor microenvironment and are associated with worse clinical outcomes in PROC. W…
View article: Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas
Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas Open
PURPOSE Outcomes for patients with advanced sarcomas are poor and there is a high unmet need to develop novel therapies. The purpose of this phase I study was to define the safety and efficacy of botensilimab (BOT), an Fc-enhanced anti–cyt…
View article: Physical, biochemical, and biological characterization of olive-derived lipid nanovesicles for drug delivery applications
Physical, biochemical, and biological characterization of olive-derived lipid nanovesicles for drug delivery applications Open
View article: Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial Open
View article: Phase <scp>II</scp> clinical trial of nab‐paclitaxel plus cisplatin plus gemcitabine (<scp>NABPLAGEM</scp>) in patients with untreated advanced pancreatic cancer
Phase <span>II</span> clinical trial of nab‐paclitaxel plus cisplatin plus gemcitabine (<span>NABPLAGEM</span>) in patients with untreated advanced pancreatic cancer Open
Background A previous phase IB/II study of nab‐paclitaxel + cisplatin + gemcitabine (NABPLAGEM) in 25 patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC) demonstrated favorable results. This phase II study…
View article: 58MO Evaluation of three pexidartinib doses in a global phase IV clinical study of patients with tenosynovial giant cell tumor (TGCT) who chose to continue treatment
58MO Evaluation of three pexidartinib doses in a global phase IV clinical study of patients with tenosynovial giant cell tumor (TGCT) who chose to continue treatment Open
In 2019, pexidartinib was US FDA-approsssved (800 mg/day TDD) for TGCT patients with severe morbidity or functional limitations not amenable to improvement with surgery. Per label, dose modifications are recommended in certain scenarios, y…
View article: P800: Non-mosaic trisomy 9: Prenatal and fetal autopsy findings with further delineation of the clinical phenotype
P800: Non-mosaic trisomy 9: Prenatal and fetal autopsy findings with further delineation of the clinical phenotype Open
Non-mosaic trisomy 9 (NMTS9), the presence of an entire additional chromosome 9 in all cells without evidence of mosaicism, is a rarely described chromosomal abnormality because the vast majority of affected pregnancies result in first-tri…
View article: 126P Evaluation of myeloid targeting agents, PY159 and PY314, in two dose expansion phase Ib trials in platinum-resistant ovarian cancer
126P Evaluation of myeloid targeting agents, PY159 and PY314, in two dose expansion phase Ib trials in platinum-resistant ovarian cancer Open
Novel treatment options are required in patients with platinum-resistant ovarian cancer (PROC). Myeloid-derived suppressor cells facilitate a hostile tumor microenvironment and are associated with worse clinical outcomes in PROC. We evalua…
View article: 692 COMMANDER-001: safety data from a phase I/II dose escalation/expansion study of SQZ-eAPC-HPV, a cell-based mRNA therapeutic cancer vaccine for HPV16+ solid tumors
692 COMMANDER-001: safety data from a phase I/II dose escalation/expansion study of SQZ-eAPC-HPV, a cell-based mRNA therapeutic cancer vaccine for HPV16+ solid tumors Open
Background Cancer vaccines aim to generate antigen-specific CD8+ T cell responses. However, their efficacy has been hampered by inefficient targeting of delivered antigens to the MHC-I complex. SQZ-eAPC-HPV is an autologous, HLA…
View article: 594 SQZ-PBMC-HPV-101: Increased overall survival in a subset of patients with recurrent, locally advanced, or metastatic HPV16<sup>+</sup>tumors treated with cell-based vaccine, SQZ-PBMC-HPV
594 SQZ-PBMC-HPV-101: Increased overall survival in a subset of patients with recurrent, locally advanced, or metastatic HPV16<sup>+</sup>tumors treated with cell-based vaccine, SQZ-PBMC-HPV Open
Background Cancer vaccines aim to generate antigen-specific CD8+ T cell responses. However, their efficacy has been hampered by inefficient targeting of delivered antigens to the MHC-I complex. Cell Squeeze® technology delivers target anti…
View article: 756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects with advanced solid tumors
756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects with advanced solid tumors Open
Background Anti-programmed cell death-1 (PD-1)/PD ligand 1 (PD-L1) checkpoint blockade has not been effective for all solid tumors and alternative therapies are needed for patients who do not respond to currently approved checkpoint inhibi…
View article: Video: Light-driven Marangoni flows
Video: Light-driven Marangoni flows Open
View article: 1919MO Efficacy and safety of botensilimab (BOT) plus balstilimab (BAL) in patients (pts) with refractory metastatic sarcoma
1919MO Efficacy and safety of botensilimab (BOT) plus balstilimab (BAL) in patients (pts) with refractory metastatic sarcoma Open
View article: 1025MO Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors
1025MO Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors Open
View article: Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors Open
Importance Inhibition of the T-cell immunoreceptor with Ig and ITIM domains (TIGIT)/poliovirus receptor pathway may amplify the antitumor immune response of atezolizumab in programmed death ligand 1–selected tumors. Objective To evaluate t…
View article: A Phase 1/2, open label dose-escalation and expansion trial of NKT2152, an orally administered HIF2α inhibitor, to investigate safety, PK, PD and clinical activity in patients with advanced ccRCC
A Phase 1/2, open label dose-escalation and expansion trial of NKT2152, an orally administered HIF2α inhibitor, to investigate safety, PK, PD and clinical activity in patients with advanced ccRCC Open
Background: Inactivation of the VHL gene leading to aberrant HIF2α activity is nearly universal in clear cell renal cell carcinoma (ccRCC). NKT2152 is a novel, potent, selective orally available HIF2α inhibitor optimized for enhanced PK ex…
View article: LBA-4 Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)
LBA-4 Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC) Open
View article: Real-time Manipulation of Liquid Droplets using Photo-responsive Surfactant
Real-time Manipulation of Liquid Droplets using Photo-responsive Surfactant Open
Fast and programmable transport of liquid droplets on a solid substrate is desirable in microfluidic, thermal, biomedical, and energy devices. Past research has focused on designing substrates with asymmetric structures or gradient wettabi…
View article: Supplementary Figure S1 from A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer
Supplementary Figure S1 from A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer Open
Supplementary Figure S1 shows the study design. The study consisted of Part A (dose escalation) and Part B (dose confirmation). In Part A, 8 dosing levels starting with 50 mg twice daily (BID) were originally planned. Estimation of the max…
View article: Data from Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i><sup>V600E</sup>-Mutant Colorectal Cancer
Data from Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i><sup>V600E</sup>-Mutant Colorectal Cancer Open
Although BRAF inhibitor monotherapy yields response rates >50% in BRAFV600-mutant melanoma, only approximately 5% of patients with BRAFV600E colorectal cancer respond. Preclinical studies suggest that th…
View article: Supplementary Figure S1 from A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer
Supplementary Figure S1 from A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer Open
Supplementary Figure S1 shows the study design. The study consisted of Part A (dose escalation) and Part B (dose confirmation). In Part A, 8 dosing levels starting with 50 mg twice daily (BID) were originally planned. Estimation of the max…
View article: Supplementary Figure S3 from A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer
Supplementary Figure S3 from A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer Open
Supplementary Figure S3 shows a heatmap of gene expression in the scale of log2 fold ratio between pre- and on-treatment tumor samples. The gene expression was obtained using the formula for a gene g: 2^[20-CT_g+HK]/1000 where CT is the cy…
View article: Supplementary Material from Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i><sup>V600E</sup>-Mutant Colorectal Cancer
Supplementary Material from Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i><sup>V600E</sup>-Mutant Colorectal Cancer Open
Supplementary Material
View article: Data from Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i><sup>V600E</sup>-Mutant Colorectal Cancer
Data from Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i><sup>V600E</sup>-Mutant Colorectal Cancer Open
Although BRAF inhibitor monotherapy yields response rates >50% in BRAFV600-mutant melanoma, only approximately 5% of patients with BRAFV600E colorectal cancer respond. Preclinical studies suggest that th…
View article: Supplementary Material from Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i><sup>V600E</sup>-Mutant Colorectal Cancer
Supplementary Material from Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i><sup>V600E</sup>-Mutant Colorectal Cancer Open
Supplementary Material
View article: Supplementary Figure from First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
Supplementary Figure from First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors Open
Supplementary Figure from First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
View article: Supplementary Table from First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
Supplementary Table from First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors Open
Supplementary Table from First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors